Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China

Capital Medical University

Status: Unknown

Conditions: NMO Spectrum Disorder;Registry Study

Treatments: Diagnostic Test: serum AQP4-antibody testing method

Study type: Observational

Funder types: Other

Identifiers

NCT03514030

2018-2

Details and patient eligibility

About

In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.In 2004, Lennon and other persons found highly specific AQP4（aquaporin 4）antibodies in NMO patients'sera, and further differentiated between NMO and MS, confirming that NMO is an independent disease.At present, NMO has been widely recognized as an idiopathic and severe demyelinating disease of the central nervous system.In 2015, the international NMO diagnostic team developed the diagnostic criteria based on highly specific AQP4 antibodie.Up to now, in China, there is no data on the number of NMOSD patients, the rate of misdiagnosis, the treatment methods, and the prognosis.This study is committed to build China's NMOSD big data platform to provide the basis for diagnosis, treatment and prognosis of the disease.

Enrollment: 400 estimated patients

Sex: All

Ages: 14+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. more than 14 years old
2. Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015

Exclusion criteria

1. less than 14 years old
2. NOT Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015

Trial design

400 participants in 2 patient groups

positive

Description:

serum AQP4-antibody is positive

Treatment:

Diagnostic Test: serum AQP4-antibody testing method

negtive

Description:

serum AQP4-antibody is negtive

Treatment:

Diagnostic Test: serum AQP4-antibody testing method